Morgans Sticks to Their Buy Rating for Mineral Resources Limited (MALRF)
Confident Investing Starts Here:
According to TipRanks, Sleeman is an analyst with an average return of -13.5% and a 27.27% success rate. Sleeman covers the Basic Materials sector, focusing on stocks such as Evolution Mining , Liontown Resources Limited, and Mineral Resources Limited.
In addition to Morgans, Mineral Resources Limited also received a Buy from Morgan Stanley's Rahul Anand in a report issued on May 26. However, on May 27, J.P. Morgan maintained a Hold rating on Mineral Resources Limited (Other OTC: MALRF).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
Citi Keeps Their Buy Rating on Inmobiliaria Colonial (0RID)
In a report released today, Aaron Guy from Citi maintained a Buy rating on Inmobiliaria Colonial, with a price target of €7.50. The company's shares closed last Friday at €5.95. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Guy covers the Real Estate sector, focusing on stocks such as Derwent London plc REIT, Safestore Holdings, and Inmobiliaria Colonial. According to TipRanks, Guy has an average return of -0.3% and a 54.55% success rate on recommended stocks. Currently, the analyst consensus on Inmobiliaria Colonial is a Hold with an average price target of €6.15.
Business Insider
4 hours ago
- Business Insider
Goldman Sachs Remains a Buy on Argenx Se (ARGX)
In a report released on July 4, Richard Felton from Goldman Sachs maintained a Buy rating on Argenx Se, with a price target of $835.00. The company's shares closed last Thursday at $543.48. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Felton is a 4-star analyst with an average return of 10.2% and a 64.84% success rate. Felton covers the Healthcare sector, focusing on stocks such as Carl Zeiss Meditec, Fresenius Medical Care AG & Co. KGaA, and Fresenius SE & Co. KGaA. Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $754.09, a 38.75% upside from current levels. In a report released on July 2, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $700.00 price target.
Business Wire
4 hours ago
- Business Wire
Realbotix Integrates Multiple Languages into AI, Unlocking Global Customer Service Applications
LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (' Realbotix ' or the 'Company'), a leader in AI-powered humanoid robotics, announces that its robot now communicates fluently in 15 major languages, with access to more than 147 additional languages and dialects through cloud-based support. This multilingual capability enhances Realbotix's robots ability to connect with people across a wide range of industries and cultural contexts. With its expanded language support and ability to integrate most third party AI platforms, the robot is well suited for international venues such as airports, hotels, museums, and tourist attractions. It can provide information, answer questions, and assist visitors in the language they are most comfortable speaking, improving accessibility and overall guest experience. Lifelike in both appearance and interaction, the Realbotix robot is designed to deliver natural and engaging conversations. In healthcare settings, the robot can serve as a communication bridge between patients and medical staff. Patients can speak in their preferred language, allowing them to ask questions, describe symptoms, or share concerns. The robot then translates the information and relays it to healthcare teams, helping to ensure clearer communication and more responsive care. "Adding multilingual support to our humanoid robot is a meaningful step toward more human-centered technology," said Andrew Kiguel, CEO of Realbotix. "Whether in a hospital or a hotel, the ability to understand and respond in someone's native language builds trust and makes the experience more personal." Realbotix continues to enhance its AI platform with advanced speech, emotional recognition, and lifelike interaction, offering customizable robotic solutions for industries including hospitality, healthcare, and customer service. Businesses interested in inquiring about our robots can contact sales@ About Realbotix Realbotix designs and manufactures AI -powered humanoid robots that improve human experiences through connection, companionship and intelligent interaction. Manufactured in the United States, Realbotix specializes in realistic, customizable robots built for entertainment, customer service, and personal well-being. Our patented AI and robotics technologies enable lifelike expression, motion, and social engagement, making us a category leader in the rapidly evolving field of human-centric robotics. Product site Corporate and Investor site Keep up-to-date on Realbotix developments by joining our online communities on Twitter, LinkedIn, and YouTube. Follow Aria, our humanoid robot, on Instagram and TikTok. Forward-Looking Statements This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend' and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, as described in more detail in our securities filings available at Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
